uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study
Show others and affiliations
2013 (English)In: The Lancet, ISSN 0140-6736, E-ISSN 1474-547X, Vol. 382, no 9894, 790-796 p.Article in journal (Refereed) Published
Abstract [en]

Background VKORC1 and CYP2C9 are important contributors to warfarin dose variability, but explain less variability for individuals of African descent than for those of European or Asian descent. We aimed to identify additional variants contributing to warfarin dose requirements in African Americans. Methods We did a genome-wide association study of discovery and replication cohorts. Samples from African-American adults (aged >= 18 years) who were taking a stable maintenance dose of warfarin were obtained at International Warfarin Pharmacogenetics Consortium (IWPC) sites and the University of Alabama at Birmingham (Birmingham, AL, USA). Patients enrolled at IWPC sites but who were not used for discovery made up the independent replication cohort. All participants were genotyped. We did a stepwise conditional analysis, conditioning first for VKORC1 -1639G -> A, followed by the composite genotype of CYP2C9*2 and CYP2C9*3. We prespecified a genome-wide significance threshold of p<5x10(-8) in the discovery cohort and p<0.0038 in the replication cohort. Findings The discovery cohort contained 533 participants and the replication cohort 432 participants. After the prespecified conditioning in the discovery cohort, we identified an association between a novel single nucleotide polymorphism in the CYP2C cluster on chromosome 10 (rs12777823) and warfarin dose requirement that reached genome-wide significance (p=1.51x10(-8)). This association was confirmed in the replication cohort (p=5.04x10(-5)); analysis of the two cohorts together produced a p value of 4.5x10(-12). Individuals heterozygous for the rs12777823 A allele need a dose reduction of 6.92 mg/week and those homozygous 9.34 mg/week. Regression analysis showed that the inclusion of rs12777823 significantly improves warfarin dose variability explained by the IWPC dosing algorithm (21% relative improvement). Interpretation A novel CYP2C single nucleotide polymorphism exerts a clinically relevant effect on warfarin dose in African Americans, independent of CYP2C9*2 and CYP2C9*3. Incorporation of this variant into pharmacogenetic dosing algorithms could improve warfarin dose prediction in this population.

Place, publisher, year, edition, pages
2013. Vol. 382, no 9894, 790-796 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-209174DOI: 10.1016/S0140-6736(13)60681-9ISI: 000324239200029OAI: oai:DiVA.org:uu-209174DiVA: diva2:656195
Available from: 2013-10-15 Created: 2013-10-15 Last updated: 2016-02-19

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Wadelius, Mia
By organisation
Clinical pharmacogenomics and osteoporosis
In the same journal
The Lancet
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 181 hits
ReferencesLink to record
Permanent link

Direct link